Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2009 - 10 - 20

Menarini is granted European rights to Adenuric®, innovative drug for chronic hyperuricaemia in gout.

Menarini is granted European rights to Adenuric®, innovative drug for chronic hyperuricaemia in gout.

Ipsen and Menarini announced today the signature of an agreement under which Ipsen, an innovation-driven international specialty pharmaceutical group, grants Menarini exclusive rights for 41 countries for Adenuric® (febuxostat), a novel treatment for gout.

Adenuric® is a molecule of Japanese origin, developed by Teijin Pharma Ltd., Tokyo, Japan.

The agreement covers the European Union, Eastern Europe including Russia, Ukraine and Belarus, as well as Switzerland, Iceland, Norway, Armenia and Georgia. Ipsen retains co-promotion rights for France.

Gout, a particularly painful condition, is the most common form of arthritis in men, caused by high levels of uric acid in the body. Crystals of monosodium urate are deposited on the articular cartilage of joints, tendons, and surrounding tissues and may lead to masses called ‘tophi’.
The condition is marked by painful attacks of acute arthritis and can eventually lead to chronic gouty arthritis.

In the absence of treatment, symptomatic chronic hyperuricaemia may become crippling and lead to a noticeable degradation in the quality of life linked to articular and/or renal impairment (lithiasis, nephropathy).

Adenuric® is the first product to be made available to patients after many decades without any substantial innovation in the treatment of hyperuricaemia in gout. This break-through product addresses a high unmet medical need.

Adenuric® has proven therapeutic superiority to allopurinol (the current treatment of choice in gout) and is also well tolerated by patients with mild and moderate renal impairment.

"Research in new treatments for gout has been absent for nearly forty years, making it an orphan disease in some respects” declared Dr. Alberto Aleotti, Chairman and Chief Executive Officer of the Menarini Group “ We are therefore extremely proud that Ipsen has chosen Menarini as the ideal partner to substantially contribute to European patients’ health with an innovative drug in this therapeutic area".

Menarini expects to launch Adenuric® at the beginning of 2010. Menarini will also directly undertake to carry out further clinical research on the product.

October 20, 2009